Sinopharm Hyundai (600420.SH): Drugs such as injectable ceftazidime and avibactan sodium will be selected for centralized procurement of drugs nationwide

Zhitongcaijing · 1d ago

Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. On July 31, 2026, some of the company's subsidiaries participated in the 12th batch of centralized national drug procurement work organized by the State Drug Joint Procurement Office (Joint Procurement Office for short), and some drugs will be selected for this centralized procurement.

Among the products selected above, diclofenac sodium extended-release tablets, injectable ceftazidime avibactan sodium, and vitamin B6 injections totaled 348 million yuan in 2025, accounting for about 3.72% of the company's revenue in 2025; pentanediquil hydrochloride injections and bumetanib injections are new products for which the company obtained a drug registration certificate in 2025, and have not yet generated sales revenue. The calcium folic acid injection that Sinopharm Yixin Pharmaceutical Co., Ltd. participated in the collection was not selected, and the product did not achieve sales revenue in 2025.

The selected price of the drug to be selected this time has decreased to a certain extent compared to the original regional average bid price. If the selection is determined, the subsequent signing and implementation of the sales contract will help increase the sales volume and market share of related products, enhance the company's brand influence, and have a positive impact on the company's long-term development. The above matters will not have a significant impact on the company's current operating results.